Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2007Chinese Medical JournalOpen Access

Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer

View Full Paper
Ask AI
Bookmark
Share

Key result

Ginsenoside Rg3 combined with cyclophosphamide significantly inhibited growth and angiogenesis of ovarian cancer and improved survival time in mice compared to control.

Why the study?

Does the combination of ginsenoside Rg3 and cyclophosphamide inhibit growth and angiogenesis in a mouse model of human ovarian cancer?

Population

28 female athymic mice transplanted with human ovarian cancer cells (SKOV-3)

Comparison

Ginsenoside Rg3 combined with cyclophosphamide… vs Control group, Ginsenoside Rg3 alone, and CTX…

Design

Preclinical, Divided randomly into 4 groups

Authors

TXTianmin XuYXYing XinMCManhua Cui

Discussion

Loading...

Member takes

Overview

Does not support clinical use in ovarian cancer; leaves open translation of murine anti-tumor effects to human trials.

Structured PICO

Does the combination of ginsenoside Rg3 and cyclophosphamide inhibit growth and angiogenesis in a mouse model of human ovarian cancer?

P
Population
28 female athymic mice transplanted with ovarian cancer cells (SKOV-3) treated with ginsenoside Rg3 and/or cyclophosphamide for 10 days.
I
Intervention
Ginsenoside Rg3 combined with cyclophosphamide (CTX) via intraperitoneal injection for 10 days
C
Comparator
Control group, Ginsenoside Rg3 alone, and CTX alone
O
Outcome
Life quality, number of living days, tumour size, tumour inhibitive rate, life elongation rate, proliferating cell nuclear antigen labelling index (PCNALI), expression of vascular endothelial cell growth factor (VEGF), and microvessel density (MVD)surrogate

In a preclinical model of ovarian cancer, the combination of ginsenoside Rg3 and cyclophosphamide synergistically inhibited tumor growth and angiogenesis while improving survival.

Cite This Study

Xu et al. (2007) studied Ovarian cancer (n=28). Ginsenoside Rg3 combined with cyclophosphamide (CTX) vs. Control, ginsenoside Rg3 alone, or CTX alone was evaluated on Tumour growth, angiogenesis, and survival time. Ginsenoside Rg3 combined with cyclophosphamide significantly inhibited growth and angiogenesis of ovarian cancer and improved survival time in mice compared to control.

synapsesocial.com/papers/6a89a3b875060194fdc983fahttps://doi.org/10.1097/00029330-200704010-00011
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice2009 · 145 citations
  2. 2Synergistic effects of ginsenoside Rg3 and cyclophosphamine on tumor growth and angiogenesis in lung cancer2011 · 5 citations
  3. 3Ginsenoside Rg3 enhances the inhibitory effects of chemotherapy on esophageal squamous cell carcinoma in mice2014 · 29 citations
  4. 4Ginsenoside Rg3 Prolongs Survival of the Orthotopic Hepatocellular Carcinoma Model by Inducing Apoptosis and Inhibiting Angiogenesis2019 · 29 citations
  5. 5Ginsenoside Rg3 Combined with Oxaliplatin Inhibits the Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells <i>via</i> Downregulating PCNA and Cyclin D12019 · 37 citations